HGMB1在心血管疾病严重程度的诊断、预后的研究进展
Research Progress of HGMB1 in the Diagnosis and Prognosis of Cardiovascular Disease Severity
摘要: 随着人们饮食的多样性，随着经济水平的升高，随着晚睡的生活方式越来越普遍，心脑血管疾病的发病率逐渐升高，尤其是心血管疾病，心血管疾病是当前全球死亡的主要原因，早发现、早诊断及早治疗在心血管疾病的预后起到了不可代替的作用。其中血指标，如肌钙蛋白、肌酸激酶同工酶等，对早发现、早诊断起到了至关重要的作用，但血指标同时在其他疾病中也会明显升高，如肌钙蛋白、肌酸激酶同工酶在炎症性疾病中也会升高，寻找更多评估心血管疾病的血指标显得尤为重要及急迫。近年来研究发现，高迁移率族蛋白1 (HGMB1)参与冠心病、心肌炎、心力衰竭、心房纤颤、高血压等心血管疾病的进程，进一步辅助心血管疾病的诊断及指导心血管疾病的预后。本文就HMGB1心血管疾病的诊断及预后的作用研究的进展做一综述。
Abstract: With the increasing diversity of people’s diets, the rising economic standards, and the growing prevalence of late-night lifestyles, the incidence of cardiovascular and cerebrovascular diseases is gradually increasing, especially cardiovascular diseases. Cardiovascular diseases are the main causes of global death. Early detection, early diagnosis and early treatment play an irreplaceable role in the prognosis of cardiovascular diseases. Among them, blood indicators, such as troponin and creatine kinase isoenzyme, play a vital role in early detection and early diagnosis. However, blood indicators will also increase significantly in other diseases. For example, troponin and creatine kinase isoenzyme will also increase inflammatory diseases. It is particularly important and urgent to find more blood indicators to evaluate cardiovascular diseases. In recent years, studies have found that high mobility group protein 1 (HGMB1) is involved in the process of cardiovascular diseases such as coronary heart disease, myocarditis, heart failure, atrial fibrillation, hypertension, etc., and further assists the diagnosis of cardiovascular diseases and guides prognosis of cardiovascular diseases. This article reviews the progress of research on the diagnosis and prognosis of HMGB1 cardiovascular disease.
文章引用：王丹, 杨萌甜, 何端, 王星玉, 潘军强. HGMB1在心血管疾病严重程度的诊断、预后的研究进展[J]. 临床医学进展, 2025, 15(1): 1613-1619. https://doi.org/10.12677/acm.2025.151216

参考文献

[1] Tang, D., Kang, R., Zeh, H.J. and Lotze, M.T. (2023) The Multifunctional Protein HMGB1: 50 Years of Discovery. Nature Reviews Immunology, 23, 824-841. [Google Scholar] [CrossRef] [PubMed]
[2] Cirillo, P., Giallauria, F., Palma, V.D., Maresca, F., Ziviello, F., Bevilacqua, M., et al. (2012) Cardiovascular Disease and High-Mobility Group Box 1—Is a New Inflammatory Killer in Town? Angiology, 64, 343-355. [Google Scholar] [CrossRef] [PubMed]
[3] Wahid, A., Chen, W., Wang, X. and Tang, X. (2021) High-Mobility Group Box 1 Serves as an Inflammation Driver of Cardiovascular Disease. Biomedicine & Pharmacotherapy, 139, Article 111555. [Google Scholar] [CrossRef] [PubMed]
[4] Voong, C.K., Goodrich, J.A. and Kugel, J.F. (2021) Interactions of HMGB Proteins with the Genome and the Impact on Disease. Biomolecules, 11, Article 1451. [Google Scholar] [CrossRef] [PubMed]
[5] Dash, U.K., Mazumdar, D. and Singh, S. (2024) High Mobility Group Box Protein (HMGB1): A Potential Therapeutic Target for Diabetic Encephalopathy. Molecular Neurobiology, 61, 8188-8205. [Google Scholar] [CrossRef] [PubMed]
[6] Li, J., Wang, Z., Li, J., Zhao, H. and Ma, Q. (2024) HMGB1: A New Target for Ischemic Stroke and Hemorrhagic Transformation. Translational Stroke Research. [Google Scholar] [CrossRef] [PubMed]
[7] Hu, X., Jiang, H., Bai, Q., Zhou, X., Xu, C., Lu, Z., et al. (2009) Increased Serum HMGB1 Is Related to the Severity of Coronary Artery Stenosis. Clinica Chimica Acta, 406, 139-142. [Google Scholar] [CrossRef] [PubMed]
[8] Liu, T., Zhang, D., Zhou, Y., Han, Q., Wang, L., Wu, L., et al. (2015) Increased Serum HMGB1 Level May Predict the Fatal Outcomes in Patients with Chronic Heart Failure. International Journal of Cardiology, 184, 318-320. [Google Scholar] [CrossRef] [PubMed]
[9] Liang, W., Wei, R., Zhu, X., Li, J., Lin, A., Chen, J., et al. (2024) Downregulation of HMGB1 Carried by Macrophage-Derived Extracellular Vesicles Delays Atherosclerotic Plaque Formation through Caspase-11-Dependent Macrophage Pyroptosis. Molecular Medicine, 30, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[10] Boyer, M.J., Kimura, Y., Akiyama, T., Baggett, A.Y., Preston, K.J., Scalia, R., et al. (2020) Endothelial Cell‐Derived Extracellular Vesicles Alter Vascular Smooth Muscle Cell Phenotype through High‐Mobility Group Box Proteins. Journal of Extracellular Vesicles, 9, Article ID: 1781427. [Google Scholar] [CrossRef] [PubMed]
[11] Hilgendorf, I., Frantz, S. and Frangogiannis, N.G. (2024) Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities. Circulation Research, 134, 1718-1751. [Google Scholar] [CrossRef] [PubMed]
[12] Olejarz, W., Łacheta, D. and Kubiak-Tomaszewska, G. (2020) Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability. International Journal of Molecular Sciences, 21, Article 3946. [Google Scholar] [CrossRef] [PubMed]
[13] Mohammadmoradi, S. (2023) The Role of High Mobility Group Box-1 Pathobiology in Angiotensin II-Induced Abdominal Aortic Aneurysms. Doctoral Dissertation, University of Kentucky.
[14] Biscetti, F., Tinelli, G., Rando, M.M., Nardella, E., Cecchini, A.L., Angelini, F., et al. (2021) Association between Carotid Plaque Vulnerability and High Mobility Group Box-1 Serum Levels in a Diabetic Population. Cardiovascular Diabetology, 20, Article No. 114. [Google Scholar] [CrossRef] [PubMed]
[15] Benlier, N., Erdoğan, M.B., Keçioğlu, S., Orhan, N. and Çiçek, H. (2019) Association of High Mobility Group Box 1 Protein with Coronary Artery Disease. Asian Cardiovascular and Thoracic Annals, 27, 251-255. [Google Scholar] [CrossRef] [PubMed]
[16] 汪克定, 熊纤, 田胜兰. 沙库巴曲缬沙坦对老年冠心病患者血清NT-proBNP、Hcy和HMGB1水平及细胞因子的影响[J]. 中国老年学杂志, 2024, 44(12): 2826-2829.
[17] Foglio, E., Pellegrini, L., Russo, M.A. and Limana, F. (2022) HMGB1-Mediated Activation of the Inflammatory-Reparative Response Following Myocardial Infarction. Cells, 11, Article 216. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, X., Wang, T., Chen, Z., Wang, H., Yin, Y., Wang, L., et al. (2022) HMGB1‐Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice. Journal of the American Heart Association, 11, e023800. [Google Scholar] [CrossRef] [PubMed]
[19] Kohno, T., Anzai, T., Naito, K., Miyasho, T., Okamoto, M., Yokota, H., et al. (2008) Role of High-Mobility Group Box 1 Protein in Post-Infarction Healing Process and Left Ventricular Remodelling. Cardiovascular Research, 81, 565-573. [Google Scholar] [CrossRef] [PubMed]
[20] Arbustini, E., Giuliani, L., Di Toro, A. and Favalli, V. (2018) Inherited Cardiac Muscle Disease: Dilated Cardiomyopathy. In: Kumar, D. and Elliott, P., Eds., Cardiovascular Genetics and Genomics, Springer International Publishing, 319-366. [Google Scholar] [CrossRef] 
[21] Narumi, T., Shishido, T., Otaki, Y., Kadowaki, S., Honda, Y., Funayama, A., et al. (2015) High-Mobility Group Box 1-Mediated Heat Shock Protein Beta 1 Expression Attenuates Mitochondrial Dysfunction and Apoptosis. Journal of Molecular and Cellular Cardiology, 82, 1-12. [Google Scholar] [CrossRef] [PubMed]
[22] DeWulf, B., Minsart, L., Verdonk, F., Kruys, V., Piagnerelli, M., Maze, M., et al. (2023) High Mobility Group Box 1 (HMGB1): Potential Target in Sepsis-Associated Encephalopathy. Cells, 12, Article 1088. [Google Scholar] [CrossRef] [PubMed]
[23] Feng, W., Wang, J., Yan, X., Zhang, Q., Chai, L., Wang, Q., et al. (2021) ERK/Drp1‐Dependent Mitochondrial Fission Contributes to HMGB1‐Induced Autophagy in Pulmonary Arterial Hypertension. Cell Proliferation, 54, e13048. [Google Scholar] [CrossRef] [PubMed]
[24] Bauer, E.M., Shapiro, R., Zheng, H., Ahmad, F., Ishizawar, D., Comhair, S.A., et al. (2012) High Mobility Group Box 1 Contributes to the Pathogenesis of Experimental Pulmonary Hypertension via Activation of Toll-Like Receptor 4. Molecular Medicine, 18, 1509-1518. [Google Scholar] [CrossRef] [PubMed]
[25] Li, W., Hu, K., Yang, J., Xu, X. and Li, N. (2017) HMGB1 Affects the Development of Pulmonary Arterial Hypertension via RAGE. European Review for Medical and Pharmacological Sciences, 21, 3950-3958.
[26] Huang, Y., Su, W., Zhu, Z., Tang, L., Hu, X., Zhou, S., et al. (2016) Elevated Serum HMGB1 in Pulmonary Arterial Hypertension Secondary to Congenital Heart Disease. Vascular Pharmacology, 85, 66-72. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, J., Tian, X., Peng, Z., Li, W., Cao, Y., Li, Y., et al. (2019) HMGB1/TLR4 Promotes Hypoxic Pulmonary Hypertension via Suppressing BMPR2 Signaling. Vascular Pharmacology, 117, 35-44. [Google Scholar] [CrossRef] [PubMed]
[28] Hu, X., Jiang, H., Bai, Q., Zhou, X., Xu, C., Lu, Z., et al. (2009) Increased Serum HMGB1 Is Related to the Severity of Coronary Artery Stenosis. Clinica Chimica Acta, 406, 139-142. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, L., Zhang, B., Yu, Y., Wang, J., Wu, J., Su, Y., et al. (2021) Angiotensin II Increases HMGB1 Expression in the Myocardium through AT1 and AT2 Receptors When under Pressure Overload. International Heart Journal, 62, 162-170. [Google Scholar] [CrossRef] [PubMed]
[30] Bangert, A., Andrassy, M., Müller, A., Bockstahler, M., Fischer, A., Volz, C.H., et al. (2015) Critical Role of RAGE and HMGB1 in Inflammatory Heart Disease. Proceedings of the National Academy of Sciences, 113, E155-E164. [Google Scholar] [CrossRef] [PubMed]
[31] Cicchinelli, S., Pignataro, G., Gemma, S., Piccioni, A., Picozzi, D., Ojetti, V., et al. (2024) PAMPs and DAMPs in Sepsis: A Review of Their Molecular Features and Potential Clinical Implications. International Journal of Molecular Sciences, 25, Article 962. [Google Scholar] [CrossRef] [PubMed]
[32] Andrassy, M., Volz, H.C., Riedle, N., Gitsioudis, G., Seidel, C., Laohachewin, D., et al. (2011) HMGB1 as a Predictor of Infarct Transmurality and Functional Recovery in Patients with Myocardial Infarction. Journal of Internal Medicine, 270, 245-253. [Google Scholar] [CrossRef] [PubMed]
[33] Gui, Y., Sun, J., You, W., Wei, Y., Tian, H. and Jiang, S. (2020) Glycyrrhizin Suppresses Epithelial-Mesenchymal Transition by Inhibiting High-Mobility Group Box1 via the TGF-β1/Smad2/3 Pathway in Lung Epithelial Cells. PeerJ, 8, e8514. [Google Scholar] [CrossRef] [PubMed]
[34] Yu, C., Xiang, Y., Zhang, M., Wen, J., Duan, X., Wang, L., et al. (2024) Glycyrrhizic Acid Alleviates Semen Strychni-Induced Neurotoxicity through the Inhibition of HMGB1 Phosphorylation and Inflammatory Responses. Journal of Neuroimmune Pharmacology, 19, Article No. 21. [Google Scholar] [CrossRef] [PubMed]
[35] Campana, L., Bosurgi, L., Bianchi, M.E., Manfredi, A.A. and Rovere-Querini, P. (2009) Requirement of HMGB1 for Stromal Cell-Derived Factor-1/CXCL12-Dependent Migration of Macrophages and Dendritic Cells. Journal of Leukocyte Biology, 86, 609-615. [Google Scholar] [CrossRef] [PubMed]
[36] Perazzi, M., Piffero, R., Minisini, R., et al. (2023) High Mobility Group Box-1 as a Candidate Biomarker of Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma. Preprints. [Google Scholar] [CrossRef] 
[37] Zheng, X., Lu, J., Liu, J., Zhou, L. and He, Y. (2023) HMGB Family Proteins: Potential Biomarkers and Mechanistic Factors in Cardiovascular Diseases. Biomedicine & Pharmacotherapy, 165, Article 115118. [Google Scholar] [CrossRef] [PubMed]

为你推荐